Michael Brosman, MD
Ophthalmology · Wilmington, DENPI 1720032832
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 225 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations.
Across 225 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$669
- Bausch & Lomb Americas Inc.$637
- Novartis$515
- Alcon$483
- Regeneron Healthcare Solutions, Inc.$470
- Tarsus Pharmaceuticals, Inc.$254
- plus $2K from 22 others
Across 7 payments — averaging $2571.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$18K
What the payments were for
- Food & beverage$4,52799%
- Gifts$391%
- Other$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 27 | $669 |
| Bausch & Lomb Americas Inc. | 27 | $637 |
| Novartis | 29 | $515 |
| Alcon | 28 | $483 |
| Regeneron Healthcare Solutions, Inc. | 26 | $470 |
| Tarsus Pharmaceuticals, Inc. | 11 | $254 |
| AbbVie(2 entities) | 8 | $206 |
| Amgen(2 entities) | 10 | $148 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $136 |
| Biotissue Holdings Inc. | 6 | $126 |
| Mallinckrodt Hospital Products Inc. | 5 | $112 |
| Aerie Pharmaceuticals, Inc. | 6 | $111 |
| Oyster Point Pharma, Inc. | 6 | $103 |
| Kala Pharmaceuticals, Inc. | 5 | $103 |
| Johnson & Johnson Vision Care, Inc. | 4 | $81 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $71 |
| Rxsight Inc | 2 | $50 |
| Sight Sciences, Inc. | 2 | $48 |
| Carl Zeiss Meditec USA, Inc. | 2 | $40 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Dompe US, Inc. | 1 | $33 |
| Astellas Pharma US Inc | 1 | $32 |
| Harrow Eye, LLC | 2 | $28 |
| Coopervision Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $21 |
| NEW World Medical,inc. | 1 | $18 |
| Thea Pharma Inc. | 1 | $15 |
| Ocular Therapeutix, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,588 in reported general payments places this provider in the 80th percentile of 49 ophthalmology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 239 | $318,792 |
| RestasisCyclosporine | 120 | $159,962 |
| CequaCyclosporine | 71 | $83,289 |
| ProlensaBromfenac Sodium | 181 | $62,744 |
| RocklatanNetarsudil Mesylat/Latanoprost | 117 | $53,835 |
| LumiganBimatoprost | 64 | $32,393 |
| RhopressaNetarsudil Mesylate | 22 | $17,477 |
| Prednisolone Acetate | 452 | $17,410 |
| Restasis MultidoseCyclosporine | 19 | $15,766 |
| MieboPerfluorohexyloctane/Pf | 18 | $14,698 |
| IlevroNepafenac | 37 | $13,380 |
| Brimonidine Tartrate | 107 | $12,731 |
| Travoprost | 51 | $10,546 |
| Latanoprost | 774 | $10,272 |
| MoxifloxacinMoxifloxacin Hcl | 363 | $9,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $637 | $333,490257 claims |
| AbbVieRestasis, Lumigan, Restasis Multidose, Combigan | $206 | $216,288221 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $669 | $83,28971 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $111 | $71,312139 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $136 | $62,744181 claims |
| NovartisIlevro, Travatan Z | $515 | $17,69949 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $103 | $7,94613 claims |
| AlconSimbrinza | $483 | $7,82232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 49 ophthalmology providers in Delaware.
Other ophthalmology in Wilmington
- Jeffrey MinkovitzWilmington$7K
- Heather DealyWilmington$6K
- Stewart SmithWilmington$6K
- Richard SherryWilmington$5K
- Brian ToussaintWilmington$2K
- Sean ConsidineWilmington$2K
- Tabassum AliWilmington$2K
- Paula KoWilmington$2K
- Harry LebowitzWilmington$2K
- Charles WangWilmington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.